1. Home
  2. CNM vs KYMR Comparison

CNM vs KYMR Comparison

Compare CNM & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core & Main Inc.

CNM

Core & Main Inc.

HOLD

Current Price

$43.93

Market Cap

9.0B

ML Signal

HOLD

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$106.53

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNM
KYMR
Founded
1996
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Durable Goods
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
9.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CNM
KYMR
Price
$43.93
$106.53
Analyst Decision
Buy
Strong Buy
Analyst Count
11
26
Target Price
$61.55
$107.72
AVG Volume (30 Days)
2.1M
671.1K
Earning Date
06-09-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
8.45
N/A
EPS
0.57
N/A
Revenue
$7,647,000,000.00
$39,211,000.00
Revenue This Year
$4.89
$10.61
Revenue Next Year
$4.21
$8.17
P/E Ratio
$76.58
N/A
Revenue Growth
2.77
N/A
52 Week Low
$42.50
$36.88
52 Week High
$67.18
$130.05

Technical Indicators

Market Signals
Indicator
CNM
KYMR
Relative Strength Index (RSI) 41.08 48.35
Support Level $42.50 $76.40
Resistance Level $54.69 $120.37
Average True Range (ATR) 1.35 5.21
MACD -0.02 -1.91
Stochastic Oscillator 33.57 5.87

Price Performance

Historical Comparison
CNM
KYMR

About CNM Core & Main Inc.

Core & Main is a leading specialty distributor with a focus on water, wastewater, storm drainage, and fire protection products. The company provides solutions to municipalities, private water companies, and professional contractors across municipal, nonresidential, and residential end markets. The company's specialty products and services are used in the maintenance, repair, replacement, and construction of water and fire protection infrastructure.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Share on Social Networks: